v3.26.1
Schedule of Segment Reporting Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Revenue $ 21,796  
Cost of goods sold 4,231
Research and development 2,086,574 492,660
Selling, general and administrative 6,839,712  
Segment net loss (8,908,721)  
Other interest income (expense), net 263,824 651,657
Net operating loss (8,644,897) $ (2,439,625)
Reportable Geographical Components [Member]    
Segment Reporting Information [Line Items]    
Revenue 21,796  
Cost of goods sold 4,231  
Research and development 2,086,574  
Selling, general and administrative 1,997,046  
Segment net loss (4,066,055)  
Other interest income (expense), net  
Net operating loss (4,066,055)  
Pharmaceutical Operations [Member] | Reportable Geographical Components [Member]    
Segment Reporting Information [Line Items]    
Revenue  
Cost of goods sold  
Research and development 2,086,574  
Selling, general and administrative 817,554  
Segment net loss (2,904,128)  
Other interest income (expense), net  
Net operating loss (2,904,128)  
Premium Nutritional Supplements [Member] | Reportable Geographical Components [Member]    
Segment Reporting Information [Line Items]    
Revenue 21,796  
Cost of goods sold 4,231  
Research and development  
Selling, general and administrative 1,179,492  
Segment net loss (1,161,927)  
Other interest income (expense), net  
Net operating loss (1,161,927)  
Corporate Segment and Other Operating Segment [Member] | Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]    
Segment Reporting Information [Line Items]    
Revenue  
Cost of goods sold  
Research and development  
Selling, general and administrative 4,842,666  
Segment net loss (4,842,666)  
Other interest income (expense), net 263,824  
Net operating loss $ (4,578,842)